Literature DB >> 17299095

Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival.

Adrian Wiestner1, Mahsa Tehrani, Michael Chiorazzi, George Wright, Federica Gibellini, Kazutaka Nakayama, Hui Liu, Andreas Rosenwald, H Konrad Muller-Hermelink, German Ott, Wing C Chan, Timothy C Greiner, Dennis D Weisenburger, Julie Vose, James O Armitage, Randy D Gascoyne, Joseph M Connors, Elias Campo, Emilio Montserrat, Francesc Bosch, Erlend B Smeland, Stein Kvaloy, Harald Holte, Jan Delabie, Richard I Fisher, Thomas M Grogan, Thomas P Miller, Wyndham H Wilson, Elaine S Jaffe, Louis M Staudt.   

Abstract

A gene expression signature of tumor proliferation rate in mantle cell lymphoma (MCL) is an overriding molecular predictor of the length of survival following diagnosis. Many strongly proliferative MCL tumors have exceptionally high cyclin D1 mRNA levels and preferentially express short cyclin D1 mRNA isoforms. We demonstrate here that these short mRNAs are cyclin D1a isoforms with truncated 3'UTRs, not alternatively spliced cyclin D1b mRNA isoforms. Among 15 MCL tumors with truncated cyclin D1 mRNAs, 7 had genomic deletions in the CCND1 3'UTR region. In 3 others, CCND1 contained point mutations that created premature polyadenylation signals, giving rise to 1.5-kb mRNAs lacking most of the 3'UTR. Both types of genomic alteration created transcripts lacking mRNA destabilization elements present in the wild-type cyclin D1a mRNA. Premature polyadenylation due to a 3'UTR mutation also was present in the Z-138 MCL cell line, which expressed both truncated and full-length cyclin D1a mRNAs. In these cells, the half-life of the short cyclin D1a mRNA was much longer than that of the full-length mRNA. We conclude that alterations of CCND1 3'UTR structure can significantly increase its oncogenic effect and worsen the clinical course of MCL patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17299095      PMCID: PMC1885523          DOI: 10.1182/blood-2006-08-039859

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

Review 1.  Post-transcriptional regulation of gene expression by degradation of messenger RNAs.

Authors:  Annamaria Bevilacqua; Maria Cristina Ceriani; Sergio Capaccioli; Angelo Nicolin
Journal:  J Cell Physiol       Date:  2003-06       Impact factor: 6.384

Review 2.  Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs.

Authors:  David P Bartel; Chang-Zheng Chen
Journal:  Nat Rev Genet       Date:  2004-05       Impact factor: 53.242

Review 3.  bcl-1, t(11;14), and mantle cell-derived lymphomas.

Authors:  M Raffeld; E S Jaffe
Journal:  Blood       Date:  1991-07-15       Impact factor: 22.113

4.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.

Authors:  Andreas Rosenwald; George Wright; Adrian Wiestner; Wing C Chan; Joseph M Connors; Elias Campo; Randy D Gascoyne; Thomas M Grogan; H Konrad Muller-Hermelink; Erlend B Smeland; Michael Chiorazzi; Jena M Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Sarah Henrickson; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Emilio Montserrat; Francesc Bosch; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Richard I Fisher; Thomas P Miller; Michael LeBlanc; German Ott; Stein Kvaloy; Harald Holte; Jan Delabie; Louis M Staudt
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

5.  Genotypic characterization of centrocytic lymphoma: frequent rearrangement of the chromosome 11 bcl-1 locus.

Authors:  M E Williams; C D Westermann; S H Swerdlow
Journal:  Blood       Date:  1990-10-01       Impact factor: 22.113

6.  Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation.

Authors:  M Seto; K Yamamoto; S Iida; Y Akao; K R Utsumi; I Kubonishi; I Miyoshi; T Ohtsuki; Y Yawata; M Namba
Journal:  Oncogene       Date:  1992-07       Impact factor: 9.867

7.  Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation.

Authors:  David A Solomon; Ying Wang; Sejal R Fox; Tah C Lambeck; Sarah Giesting; Zhengdao Lan; Adrian M Senderowicz; Claudio J Conti; Erik S Knudsen
Journal:  J Biol Chem       Date:  2003-05-12       Impact factor: 5.157

8.  Human D-type cyclin.

Authors:  Y Xiong; T Connolly; B Futcher; D Beach
Journal:  Cell       Date:  1991-05-17       Impact factor: 41.582

9.  An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene.

Authors:  Fengmin Lu; Andrew B Gladden; J Alan Diehl
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

10.  Characterization of a candidate bcl-1 gene.

Authors:  D A Withers; R C Harvey; J B Faust; O Melnyk; K Carey; T C Meeker
Journal:  Mol Cell Biol       Date:  1991-10       Impact factor: 4.272

View more
  93 in total

Review 1.  Alternative mRNA polyadenylation in eukaryotes: an effective regulator of gene expression.

Authors:  Carol S Lutz; Alexandra Moreira
Journal:  Wiley Interdiscip Rev RNA       Date:  2011 Jan-Feb       Impact factor: 9.957

Review 2.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Authors:  Patricia Pérez-Galán; Martin Dreyling; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

3.  High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma.

Authors:  P-Y Kuo; V V Leshchenko; M J Fazzari; D Perumal; T Gellen; T He; J Iqbal; S Baumgartner-Wennerholm; L Nygren; F Zhang; W Zhang; K S Suh; A Goy; D T Yang; W-C Chan; B S Kahl; A K Verma; R D Gascoyne; E Kimby; B Sander; B H Ye; A M Melnick; S Parekh
Journal:  Oncogene       Date:  2014-03-31       Impact factor: 9.867

4.  The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.

Authors:  Julia Slotta-Huspenina; Ina Koch; Laurence de Leval; Gisela Keller; Margit Klier; Karin Bink; Marcus Kremer; Mark Raffeld; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

Review 5.  Altered RNA Processing in Cancer Pathogenesis and Therapy.

Authors:  Esther A Obeng; Connor Stewart; Omar Abdel-Wahab
Journal:  Cancer Discov       Date:  2019-10-14       Impact factor: 39.397

Review 6.  Do mantle cell lymphomas have an 'Achilles heel'?

Authors:  Nakhle Saba; Adrian Wiestner
Journal:  Curr Opin Hematol       Date:  2014-07       Impact factor: 3.284

Review 7.  Cyclin D1, cancer progression, and opportunities in cancer treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  J Mol Med (Berl)       Date:  2016-10-02       Impact factor: 4.599

Review 8.  Molecular Pathogenesis of Mantle Cell Lymphoma.

Authors:  Alba Navarro; Sílvia Beà; Pedro Jares; Elías Campo
Journal:  Hematol Oncol Clin North Am       Date:  2020-07-22       Impact factor: 3.722

Review 9.  Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy.

Authors:  Kevin Wang; Xiangao Huang; Maurizio Di Liberto; Selina Chen-Kiang
Journal:  Hematol Oncol Clin North Am       Date:  2020-08-01       Impact factor: 3.722

10.  Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling.

Authors:  Sílvia Beà; Itziar Salaverria; Lluís Armengol; Magda Pinyol; Verónica Fernández; Elena M Hartmann; Pedro Jares; Virginia Amador; Luís Hernández; Alba Navarro; German Ott; Andreas Rosenwald; Xavier Estivill; Elias Campo
Journal:  Blood       Date:  2008-11-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.